www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

Home / Understanding big issues

National blueprint prescribes shot in the arm for drugs companies

By Wang Wen (China Daily)

Updated: 2016-03-08 08:16:21

8.03K

The constant use of phrases such as "biological medicine", "healthcare reform" and "a healthy China" in the country's 13th Five-Year Plan (2016-20) has encouraged pharmaceutical companies, both Chinese and foreign, to expand their development programs.

According to the plan, the move is intended "to strengthen the prevention and cure of infectious, chronic and endemic diseases", and a number of pharmaceutical manufacturers and medical supplies companies will adapt their research and development programs to fit the requirements.

"We have already adjusted the direction of our research to focus on market demand, in accordance with the plan," said Hu Jiqiang, chairman of Conba Group, in Hangzhou, Zhejiang province, who is a deputy to the National People's Congress.

Chronic illnesses, such as cardiovascular and respiratory obstructions, will remain the company's core field over the next five years, Hu said.

He added that Conba - which focuses on respiratory and cardiovascular diseases - is also working on eight new treatments for respiratory illness. "We expect to gain advantages in this field in the coming years," he said.

Feng Danlong, director of corporate affairs for China at Pfizer and a member of the 12th National Committee of the Chinese People's Political Consultative Conference, proposed a stronger focus on the management of dyslipidemia - excessive levels of fat in the blood - to reduce the incidence of cardiovascular disease.

Biological medicine is also referred to several times in the plan, and the government has already taken a number of steps to support the sector, according to An Kang, chairman of Hualan Biological Engineering, China's largest manufacturer of human blood products, which is based in Henan province.

"The government has given us great support with the policies related to technological research," he said.

The wording of the plan has encouraged the company to establish a research and development center that will also include an "academic workstation" that will offer opportunities for academic research, he said.

In the next five years, Hualan Bio will continue to add to its product range and narrow the gap with foreign competitors, he added.

Foreign companies also have great expectations for China's healthcare reform, which will be deepened during the period of the plan.

"We expect substantial progress in the implementation of healthcare-reform policies in the coming five years," said Yin Xudong, chairman of Novartis Greater China.

The approval process for new drugs could also be accelerated to reduce the current five-year waiting period in the introduction of innovative new drugs in China, Yin said.

The quality standards, which ensure that patients have access to safe, high-quality generic drugs, could also be raised, he said.

主站蜘蛛池模板: 69性欧美高清影院 | 欧美午夜视频一区二区 | 日韩天天摸天天澡天天爽视频 | 亚洲免费大全 | 欧美透逼 | 国产爽的冒白浆的视频高清 | 亚洲精品一区亚洲精品 | 精品欧美日韩一区二区三区 | 高清亚洲 | 成人老司机深夜福利久久 | 久久狠狠色狠狠色综合 | 欧美午夜不卡在线观看最新 | 免费精品一区二区三区在线观看 | 成年人免费视频网站 | 国产91无套剧情在线播放 | 欧美一级一极性活片免费观看 | 97高清国语自产拍中国大陆 | 久久久久久88色愉愉 | 国产高清精品自在线看 | 一区二区三区欧美在线 | 亚洲精品一级一区二区三区 | 亚洲国产一区二区三区四区五区 | 一级毛片私人影院免费 | 久久不雅视频 | 欧美成亚洲 | 国产欧美亚洲精品一区 | 99视频在线观看视频一区 | 亚洲一区二区精品视频 | 国产91av在线| 日本乱理伦片在线观看网址 | 欧美大片一区 | 91免费网站在线看入口黄 | 成人18免费视频 | 国产精品视频免费 | 一级毛片免费在线播放 | 午夜视频一区二区 | 日韩美女一区二区三区 | 久草手机在线观看 | 亚洲男女在线 | 亚洲国产高清视频在线观看 | 99久女女精品视频在线观看 |